electroCore Expands Intellectual Patent Portfolio for nVNS Technology
electroCore Granted Three New U.S. Patents
ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO). The three patents were issued on April 11, 2023, and relate to the electroCore’s non-invasive vagus nerve stimulation (nVNS) technology, including the following patents:
- US Patent Nos. 11,623,079 and 11,623,080 entitled “Vagal Nerve Stimulation Devices and Methods for Treating Medical Conditions” and “Vagal Nerve Stimulation for Dopamine-Related Conditions,” respectively. These patents generally relate to nVNS devices and methods for treating addiction and other medical conditions by releasing dopamine and/or endogenous opioids in the patient's brain.
- US Patent No. 11,623,078 entitled “Devices and Methods for Non-Invasive Vagal Nerve Stimulation.” This patent generally relates to devices and methods for modulating the vagus nerve by transmitting an electrical impulse transcutaneously through the neck of a patient, wherein the electrical impulse comprises bursts of 2 to 20 pulses having a frequency of about 10 to 35 Hz.
“electroCore continues to broaden its intellectual property portfolio, which consists of over 200 patents and patent applications,” stated Dan Goldberger, Chief Executive Officer of electroCore. “We are focused on exploring ways in which nVNS can help treat a variety of disorders, such as addiction or other dopamine-related conditions, aside from our FDA-cleared use for primary headache.”
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents providing expanded IP coverage; the possibility of future business models, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at .
Contact:
Rich Cockrell
CG Capital
404-736-3838
tal
